验证数据展示
经过测试的应用
Positive WB detected in | MDA-MB-231 cells, PC-3 cells, RAW 264.7 cells |
Positive IF/ICC detected in | A549 cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Western Blot (WB) | WB : 1:500-1:3000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
31231-1-AP targets LPXN in WB, IF/ICC, ELISA applications and shows reactivity with human, mouse samples.
经测试应用 | WB, IF/ICC, ELISA Application Description |
经测试反应性 | human, mouse |
免疫原 | LPXN fusion protein Ag34956 种属同源性预测 |
宿主/亚型 | Rabbit / IgG |
抗体类别 | Polyclonal |
产品类型 | Antibody |
全称 | leupaxin |
别名 | LDPL, LDLP |
计算分子量 | 43 kDa |
观测分子量 | 40-50 kDa |
GenBank蛋白编号 | BC019035 |
基因名称 | LPXN |
Gene ID (NCBI) | 9404 |
RRID | AB_3669911 |
偶联类型 | Unconjugated |
形式 | Liquid |
纯化方式 | Antigen affinity Purification |
UNIPROT ID | O60711 |
储存缓冲液 | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
储存条件 | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
LPXN, also known as Leupaxin, LDPL, belongs to the paxillin family. LPXN Contributes to the regulation of cell adhesion, spreading, and cell migration and acts as a negative regulator in integrin-mediated cell adhesion events (PMID: 20543562). LPXN has four leucine-rich LD-motifs in the N-terminus and four LIM domains in the C-terminus. It may function in cell type-specific signaling by associating with PYK2, a member of the focal adhesion kinase family (PMID: 9565592). Studies in breast cancer implicate LPXN is involved in the regulation of ER action as a co-factor (PMID: 25955236). LPXN is expressed in prostate cancer cells and its expression intensity is directly linked to PCa progression (PMID: 18451096).
实验方案
Product Specific Protocols | |
---|---|
WB protocol for LPXN antibody 31231-1-AP | Download protocol |
IF protocol for LPXN antibody 31231-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |